PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980621
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1980621
The global vascular closure devices (VCDs) market was valued at USD 2.11 billion in 2025 and is projected to grow from USD 2.28 billion in 2026 to USD 4.92 billion by 2034, registering a strong CAGR of 10.10% during 2026-2034. North America dominated the global market with a 43.30% share in 2025, supported by high healthcare expenditure, advanced hospital infrastructure, and rapid adoption of minimally invasive cardiovascular procedures.
Vascular closure devices are used to achieve hemostasis at arterial puncture sites following catheterization procedures such as angioplasty, angiography, and stent placements. Compared to manual compression, VCDs reduce hemostasis time, minimize complications, and enable early patient ambulation, making them increasingly preferred in interventional cardiology settings.
According to the National Institutes of Health, more than 1 million cardiac catheterization procedures are performed annually in the U.S. The growing number of such procedures significantly drives demand for vascular closure devices worldwide.
COVID-19 Impact
The COVID-19 pandemic negatively affected the market in 2020 due to postponement of elective cardiovascular procedures and reduced hospital visits. Healthcare systems prioritized pandemic management, leading to a temporary decline in interventional cardiology volumes and VCD demand.
However, with easing restrictions in late 2021 and increasing procedural volumes in 2022, the market recovered steadily. By 2023, procedure volumes returned to pre-pandemic levels, and sustained growth is expected throughout the 2026-2034 forecast period.
Market Trends
Introduction of Advanced Product Offerings
A prominent market trend is the development of advanced, bioresorbable, and sutureless closure devices to minimize complications such as inflammation, hematoma, and delayed hemostasis.
For example, in July 2021, Vivasure Medical Ltd. introduced PerQseal Blue, a fully bioresorbable, sutureless large-bore closure device for percutaneous cardiovascular procedures. Such innovations are enhancing procedural safety and expanding device adoption globally.
Increasing clinical trials, fundraising initiatives, and R&D investments are expected to accelerate technological advancements during the forecast period.
Market Growth Drivers
Rising Interventional Cardiology Procedures
The growing burden of cardiovascular diseases is a major driver. According to global disease statistics, ischemic heart disease affects over 244 million individuals worldwide. This surge increases demand for diagnostic and therapeutic catheter-based procedures, directly boosting VCD adoption.
Additionally, data from the Organisation for Economic Co-operation and Development shows rising angioplasty procedures across countries, including Mexico and Canada, reinforcing global procedural growth.
Economic and Clinical Benefits
VCDs provide hemostasis within approximately 5 minutes compared to more than 15 minutes with manual compression. They also reduce hospital stays and enable same-day discharge.
A study published by the National Health Service estimated potential annual savings of up to USD 5.6 million if closure devices replace manual compression. These economic advantages significantly strengthen product adoption.
Restraining Factors
Despite advantages, product recalls and safety concerns pose challenges. In April 2022, the U.S. Food and Drug Administration announced a recall of Cardinal Health's CELT ACD device due to hematoma formation risks. Sterility concerns and packaging defects also contribute to recalls, negatively affecting market confidence.
Additionally, complications such as pseudoaneurysm and arterial occlusion may restrict widespread adoption in certain clinical settings.
By Product Type
The market is segmented into plug-based and clip-based devices.
By Type
By Access Site
By End User
North America
North America generated USD 0.91 billion in 2025 and continues to dominate. The U.S. market is projected to reach USD 0.94 billion by 2026, driven by advanced healthcare infrastructure and strong presence of key players.
Europe
Europe holds the second-largest share. The UK market is estimated to reach USD 0.10 billion by 2026, while Germany is projected to reach USD 0.13 billion by 2026.
Asia Pacific
Asia Pacific is projected to grow at the highest CAGR during 2026-2034. China is estimated to reach USD 0.18 billion by 2026, Japan USD 0.05 billion, and India USD 0.13 billion, driven by rising geriatric populations and growing cardiac procedure volumes.
Competitive Landscape
Key players include Terumo Corporation, Abbott, Teleflex Incorporated, Haemonetics Corporation, Cordis, and Vivasure Medical Ltd.
In February 2024, Terumo expanded its manufacturing facility in Puerto Rico to meet rising demand for Angio-Seal VCDs, strengthening its global footprint.
Conclusion
The global vascular closure devices market is set to expand significantly from USD 2.11 billion in 2025 to USD 4.92 billion by 2034, supported by rising cardiovascular procedures, strong clinical benefits over manual compression, technological advancements, and favorable reimbursement policies. While product recalls and safety concerns present challenges, increasing procedural volumes, bioresorbable innovations, and expanding healthcare access-especially in Asia Pacific-will sustain long-term growth through 2034.
Segmentation By Product Type
By Type
By Access Site
By End-user
By Region